Sapiens · GLP-1

Ozempic in India: What It Costs, What It Treats, and How It Differs From the Rest

Ozempic arrived in India in December 2025 and became much cheaper three months later, when semaglutide came off patent here and generics arrived. Two things are still widely misunderstood. It is licensed in India for type 2 diabetes. The weight-loss licence belongs to Wegovy, which is the same molecule under a different name. And of the three drugs this page compares, semaglutide is the only one shown in placebo-controlled trials to reduce major cardiovascular events and major kidney outcomes. Tirzepatide's own outcome trial, reported in December 2025, tested that claim against an active comparator and did not overturn it.

What is Ozempic? Copy link

Ozempic is a brand name. The medicine inside is semaglutide, which belongs to a class called GLP-1 receptor agonists. It copies a hormone your gut releases after a meal: the one that tells the brain you have had enough, slows how quickly the stomach empties, and prompts the pancreas to release insulin when blood sugar is high.

The natural hormone lasts minutes. Semaglutide lasts about a week, which is what turns a mealtime signal into a steady background effect on appetite and blood sugar. It is given as a once-weekly injection under the skin.

Understanding that Ozempic is semaglutide clears up most of the confusion around the other names, because several of them contain exactly the same molecule.

It is not insulin, and the distinction matters. Insulin lowers blood sugar directly whether you need it lowered or not, which is why it can cause hypoglycaemia and weight gain. Semaglutide prompts your own insulin release mainly when blood sugar is high, so used on its own the risk of a serious low is small. Used alongside insulin or a sulfonylurea, that risk rises and those doses usually need reducing. Nor is it an SGLT2 inhibitor — that is the other newer diabetes class, drugs such as dapagliflozin and empagliflozin, which push excess glucose out through the urine. Semaglutide works upstream, on appetite and on insulin release.

Ozempic, Wegovy, Mounjaro: which is which Copy link

Most of us first meet these names in a headline, where they get used almost interchangeably. They are not interchangeable, and the differences decide what you can be prescribed and what it costs.

So Ozempic and Wegovy are the same molecule at different dose ranges, licensed for different conditions. Mounjaro is a different molecule and produces more weight loss on average, at a considerably higher price. And only the semaglutide side of that map has a generic.

The two extra names are recent. Since late 2025, Novo Nordisk has licensed second brands of both semaglutide injections to Indian partners — Extensior through Abbott for the diabetes product, Poviztra through Emcure for the weight one. They are identical pens under different labels, built for pharmacy reach beyond the metros, and part of the same brand-defence playbook that produced Yurpeak on the tirzepatide side.¹³ If a pharmacist offers one of them, you are not being switched to a generic.

Rybelsus, the daily tablet, earns its row in that table for a price reason. When Novo cut its injectable prices in March 2026, executives told Business Standard the tablet would not follow.² Its generics arrived anyway: Dr Reddy's launched oral semaglutide at ₹99 a tablet in May 2026, after Torrent's Semalix in March, which leaves Rybelsus holding its launch price while the same molecule in tablet form sells for a fraction of it.¹⁵

Ozempic price in India, by dose Copy link

Novo Nordisk launched Ozempic in India on 12 December 2025 in three pen strengths, priced by dose. Each pen holds four weekly doses, so a pen is a month.¹ On 31 March 2026, eleven days after semaglutide came off patent here, the company cut prices for the second time in five months.²

If you are on a pharmacy chain's mailing list you already know the pattern: the number on the banner and the number at checkout are not always the same. Ask which pen strength is being quoted, and whether the figure covers a month or a single dose. Pens are sold as sealed four-dose devices, so a per-dose price multiplied by four is the monthly one.

What generic semaglutide changed Copy link

Semaglutide's core Indian patents expired on 20 March 2026, and the market moved within days. Natco launched a multi-dose vial at ₹1,290 a month under the brand Semanat, Eris matched the price with Sundae, and Alkem's pre-filled pen, Semasize, came in at ₹1,800. Dr Reddy's priced its pen, Obeda, at roughly ₹4,200.³ By mid-2026 dozens of brands were on the market.

That puts the branded starting dose at roughly four times the cheapest generic, and the 1 mg maintenance dose at more than six times. The active ingredient is the same, and approved Indian generics must satisfy the CDSCO's quality and, where applicable, bioequivalence requirements for their formulation.

Put plainly: the case for the generic is arithmetic, and the case for caution is not really about the molecule. To be approved at all, an Indian generic must satisfy the regulatory requirements that apply to its semaglutide formulation: quality standards and, where applicable, bioavailability and bioequivalence studies. The active ingredient is settled chemistry. What approval examines, and what actually differs between products, is everything wrapped around the chemistry: formulation, excipients, concentration, device. The device: a vial and syringe demand a technique a pre-filled pen does not, and drawing-up errors with vials are a recognised problem. The label: several generics launched licensed for type 2 diabetes only, with weight-management labelling still pending, so the brand your pharmacy stocks may not be licensed for the reason you are taking it. And the record: the molecule's evidence transfers, but the specific product in your fridge has existed for only a few months. If cost is what stands between you and treatment, a licensed generic from an established manufacturer is a reasonable answer. If you switch, do it with your prescriber, stay on one brand even as pharmacy stock rotates, and check the strength marked on a vial carefully, because generic formats do not always mirror the pen you were on. The brand-by-brand comparison covers the individual products.

One more thing the price war created is a grey market. Semaglutide listings on B2B marketplaces, resellers on social media and unlicensed "import" sellers sit outside the regulated supply chain, and a refrigerated peptide that has travelled by unrefrigerated courier is a gamble even when it is genuine. Buy against a prescription from a licensed pharmacy, check the carton for the manufacturer and batch number, and confirm cold-chain delivery before paying for an online order.

At the pharmacy counter: what you will actually be offered Copy link

None of the sections above quite describes the experience of standing at an Indian pharmacy counter in mid-2026 with an Ozempic prescription. At least seventeen generic semaglutide products are now on the market across reusable pens, disposable pens, dose-specific vials and tablets,² and the counter has an opinion about which of them you should buy. Retail margins on domestic generics are typically wider than on Novo's brands, so the offer of a substitute is partly economics; it can still be a perfectly good offer. Recognise it as one, though: your prescriber has not seen it. In most Indian states a pharmacist is not meant to substitute a brand-name prescription without the prescriber's consent, and in practice substitution happens across counters every day. If the brand offered is not the brand written, the call belongs to your doctor.

The format decides more than the price does. The cheapest options are vials, and a vial assumes you or someone at home can draw up a precise dose with an insulin-type syringe. That is, incidentally, the exact skill set lakhs of Indian insulin users already have, and partly why the vial format launched here first in the world. If nobody in the house has ever handled a syringe, the pen premium of a few hundred rupees a month is buying dosing accuracy. Vial strengths also do not mirror the pens: a 4 mg/3 ml vial serves several weekly doses, and the millilitres-to-milligrams conversion is where dosing errors live. Have your prescriber or the dispensing pharmacist write the exact volume to draw, in ml, on the box.

Then there is the Indian summer, and anyone who has bought insulin in India already knows this drill. Every semaglutide product, branded or generic, pen or vial, needs an unbroken 2–8°C cold chain, and a May afternoon in much of the country runs above 40°C. Unopened stock belongs in a fridge at the pharmacy and in yours; an in-use pen or vial tolerates room temperature for a period stated on its own label, which in an Indian summer means the coolest room, never a car, never a windowsill. For delivery orders, the box should arrive in insulated packaging with gel packs still cold to the touch. If it arrives warm, refuse it, as you would refuse warm insulin. At the counter, ask to see the medicine taken straight from the refrigerator.

Run five checks before paying, whichever brand is in your hand. Ask for the exact brand and strength, and match both to the prescription. Ask what this particular brand is licensed for, since several generics still carry type 2 diabetes labelling only. Confirm whether you are buying a pen or a vial; for a vial, make sure the right syringes are included and get the draw volume written down. Check the batch number and expiry, and ask whether the stock has been refrigerated. Compare the quoted price with the printed MRP. A counter that answers all five without irritation is the counter to keep buying from.

What it is licensed to treat Copy link

In India, Ozempic is approved for type 2 diabetes. Not for obesity, and not for general weight loss.

The weight loss is real, and it is the reason the drug became famous. But the licensed route to semaglutide for weight management is Wegovy, which is the same molecule titrated to higher doses (up to 2.4 mg against Ozempic's 1 mg) and studied specifically in people with obesity. Prescribing Ozempic itself for weight loss is off-label: the use falls outside its approved Indian indication, so it rests on an individual clinical decision by the prescribing doctor, with the reasoning recorded — not on a default anyone is entitled to.

This matters practically. It shapes what your prescription says, which brand your insurer or employer scheme will recognise if either is involved, and what dose you can reach — Ozempic tops out below the dose used in the weight-loss trials.

The heart and kidney evidence Copy link

Semaglutide's claim here is specific, and it is worth stating precisely: placebo-controlled trials, at more than one dose, showing it reduces major cardiovascular events and major kidney outcomes. Trials that counted clinical events.

SUSTAIN-6 is the trial at Ozempic's own doses. It followed 3,297 people with type 2 diabetes at high cardiovascular risk, on semaglutide 0.5 mg or 1 mg, for two years. Major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) fell by 26% against placebo.⁴

FLOW is the kidney trial, also at an Ozempic dose. 3,533 people with type 2 diabetes and chronic kidney disease took semaglutide 1 mg weekly or placebo; over a median 3.4 years, the composite of kidney failure, a sustained halving of kidney function, or death from kidney or cardiovascular causes was 24% lower on semaglutide, major cardiovascular events were 18% lower and death from any cause 20% lower. The trial was stopped early because the benefit was already clear.¹⁰ For the large number of Indian patients whose diabetes travels with early kidney disease — the group a baseline creatinine and eGFR exists to find — this is arguably the most consequential result on this page.

SELECT asked the question in people who did not have diabetes at all: 17,604 adults aged 45 and over with a BMI of 27 or more and established heart disease. Over roughly three years, major cardiovascular events occurred in 6.5% on semaglutide against 8.0% on placebo, a 20% relative reduction, and a kidney analysis from the same trial found the composite kidney endpoint lower too.⁵ One caveat the heading hides: SELECT used semaglutide 2.4 mg, the Wegovy dose, not Ozempic's. So the ladder of evidence runs cleanly by dose — SUSTAIN-6 carries the cardiovascular claim at Ozempic doses, FLOW carries the kidney claim at Ozempic's 1 mg, and SELECT carries the cardiovascular claim at the higher dose sold as Wegovy.

Read those carefully, because the headline number does a lot of work here. SELECT recruited people who already had cardiovascular disease, so it does not tell you what happens to a healthy 35-year-old taking semaglutide for twelve kilograms. And 16.6% of the semaglutide group stopped because of side effects, against 8.2% on placebo. But within its population the finding is unusually solid: this is a weight-loss drug that has been shown to prevent cardiovascular events, which is not something most weight-loss interventions can claim.

And tirzepatide now has its own cardiovascular outcomes trial. SURPASS-CVOT, published in December 2025, randomised 13,165 people with type 2 diabetes and established cardiovascular disease to tirzepatide or dulaglutide — an active comparator with proven cardiovascular benefit of its own, not a placebo. Over a median of four years, major cardiovascular events occurred in 12.2% on tirzepatide against 13.1% on dulaglutide: non-inferior, though not statistically superior.⁹ Four months after the primary results, a post-hoc analysis in JAMA Cardiology asked a broader question: with all-cause mortality, coronary revascularisation, heart-failure admission and kidney events added to the composite, the expanded endpoint came out 16% lower on tirzepatide.¹⁴ Post-hoc, so hypothesis-generating rather than definitive, and best kept separate from the trial's primary answer: tirzepatide was non-inferior to dulaglutide for major cardiovascular events. The comparison is therefore narrower than it used to be, and more interesting for it. Semaglutide remains the one shown superior to placebo, at doses spanning both of its brands. For an Indian patient with type 2 diabetes and heart or kidney disease, that placebo-controlled evidence is still a genuine argument for semaglutide, independent of price — but the difference between the two drugs is now one of trial design, not of a missing trial. The tirzepatide side of the story is covered in full in the Mounjaro guide.

How much weight people lose Copy link

The weight-loss evidence for semaglutide comes mostly from the STEP programme, which used the 2.4 mg dose sold as Wegovy, well above Ozempic's maximum of 1 mg. In STEP-1, 1,961 adults with obesity and without diabetes took semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle support. Average weight change was −14.9% against −2.4% on placebo.⁶

That is the answer to a slightly different question, though. At the doses actually sold as Ozempic, the best guide is SUSTAIN-7, a 40-week head-to-head in people with type 2 diabetes on metformin: average weight loss of 4.6 kg at 0.5 mg and 6.5 kg at 1 mg, from a baseline near 95 kg.¹¹ Mid-single-digit kilograms works out to roughly five to seven percent of body weight; the famous fifteen belongs to the higher dose. The trial was open-label and everyone in it had diabetes, which tends to blunt drug-driven weight loss, so treat those numbers as a reference range with wide individual spread.

The ladder, then: Ozempic doses, mid-single-digit kilograms; Wegovy's 2.4 mg, about 15%; tirzepatide at full dose, 20.2% against semaglutide's 13.7% in the direct trial.⁷ Semaglutide is the cheaper molecule with the placebo-controlled cardiovascular evidence; tirzepatide is the more effective one for weight. Which matters more depends on why you are taking it.

How Ozempic is dosed Copy link

Ozempic starts at 0.25 mg once weekly for four weeks. That is an initiation dose, not yet a maintenance one, intended to let the gut adapt. Do not rush it: most of the miserable nausea stories start with a hurried ladder. It then moves to 0.5 mg, and to 1 mg if further blood sugar control is needed, with at least four weeks at each step.

Each step up is where tolerability gets tested. Gastrointestinal effects cluster around dose increases, and if they are significant the next step may need delaying or the plan reassessing with the prescribing doctor. The maximum is not a target: dose is set by response and tolerability, and plenty of blood sugar control is achieved at 0.5 mg.

Injections go into the abdomen, thigh or upper arm, on the same day each week, with or without food. If you miss a dose, there are rules about how late is too late to take it. Those are in the leaflet, and worth reading once.

Storage

Store unused pens in the fridge at 2–8°C, in the original carton, away from light, never frozen. Once a pen is in use there is a permitted room-temperature window; follow the limits printed in the leaflet supplied with your product, and do not exceed the stated temperature or time. If you buy online, confirm cold-chain delivery before you pay.

Who it is for, and who it is not Copy link

Ozempic is licensed here for adults with type 2 diabetes, usually where blood sugar is not controlled on other treatment, and often where weight or cardiovascular risk make a GLP-1 the sensible next step ahead of a sulfonylurea or insulin.

For weight without diabetes, the licensed semaglutide is Wegovy. Indian consensus guidance defines obesity at a BMI of 25 and overweight at 23, with abdominal obesity at a waist above 90 cm in men or 80 cm in women. Those are lower than the international 30 and 25. The reason is body composition: at any given BMI, South Asians carry more fat, and more of it sits around the organs.⁸ Those thresholds define obesity for diagnosis. They do not automatically become prescribing criteria, and treating the two as the same thing is a common error.

When it should not be used

The reasons to avoid it sort into three tiers, and they behave differently:

Contraindicated. A personal or family history of medullary thyroid carcinoma, or MEN2 syndrome. A previous serious hypersensitivity reaction to semaglutide or any component of the formulation.

Not indicated. Type 1 diabetes, where it does not replace insulin. Pregnancy: semaglutide should be stopped at least two months before a planned pregnancy, because of the drug's long half-life. That is a longer washout than tirzepatide requires, which catches people out when they switch. And weight loss purely for appearance, where weight is not medically a problem: a disease-management drug being asked to do cosmetic work.

Requires assessment first. Pancreatitis in the past, gallbladder disease, meaningful kidney or liver impairment, and diabetic retinopathy — which worsened early in SUSTAIN-6 among people with existing eye disease whose glucose fell quickly. Severe gastroparesis and other active gut disease call for individual judgement.

One interaction to raise: taken with insulin or a sulfonylurea, the risk of hypoglycaemia climbs, and the insulin or sulfonylurea dose usually needs lowering to compensate. Since type 2 diabetes is the licensed indication in India, that combination is common here. Alcohol can add to that hypoglycaemia risk, particularly when meals are skipped or small.

Side effects and what to do about them Copy link

The common ones are, of course, gastrointestinal: nausea, constipation, diarrhoea, vomiting, reflux, and a reduced appetite that is the drug working rather than a side effect. They are worst in the days after a dose increase and settle as the body adapts. Smaller meals, eating more slowly, stopping at the first sign of fullness and drinking enough water all help.

The serious but uncommon problems to know by name are pancreatitis, gallbladder disease and severe dehydration from persistent vomiting. Each has a clear signal, listed below. The management across this class is much the same, and the fuller guide to GLP-1 side effects goes through it properly.

Two effects that get less attention than they deserve. Rapid weight loss of any kind takes muscle along with fat unless you work at preventing it, which matters more in India where protein intake is often low and resistance training uncommon. And losing a lot of weight quickly is a recognised trigger for a diffuse hair shed two to three months later — frightening, temporary, and useful to be able to tell apart from the kind that does not grow back. Rapid loss also tends to show in the face before anywhere else, as volume leaves the cheeks and temples. It is cosmetic, and it is reversible, but people are rarely warned about it.

Tests to have before you start Copy link

Skipping the baseline is the most common shortcut and the least defensible one. Book the panel before the first prescription, and carry the report to the consult. Blood work before the first dose establishes whether the blood sugar is the whole story, or whether something quieter sits behind it, gives every later reading something to be compared against, and once in a while rewrites the plan before it starts.

If the thyroid does come back abnormal, treating it helps, though it rarely explains as much of the weight as people hope. And what a checkup includes and what to do with the result covers how these fit together.

When to see a doctor Copy link

Twice by default: once before the first dose, for eligibility, baselines and an exit plan, and again at every dose change, which should be doctor-led.

In between, a short list of symptoms should jump the queue. Severe upper abdominal pain that bores through to the back and arrives with vomiting is the signature of pancreatitis and needs same-day assessment. So does vomiting that will not stop, or an inability to hold fluids down; yellowing of the skin or eyes; pain under the right ribs after fatty food; anything new or worsening with vision; and the signs of drying out, such as passing very little urine.

And if side effects make the current dose intolerable, holding at a lower dose usually beats abandoning treatment altogether — a call best made with someone who knows your history.

This article is for general information and is not a substitute for individual medical advice. Ozempic is a prescription-only medicine and should be started, adjusted and stopped only under the supervision of a registered medical practitioner who has assessed your history, examination and baseline tests. Prices are dated market references reviewed on 7 August 2026 and change frequently.